Medigen Vaccine Biologics Corp (高端疫苗) yesterday reported positive results from an interim analysis of phase 2 trials for its COVID-19 vaccine, saying that the vaccine demonstrated high seroconversion rates and geometric mean titer (GMT) figures.
A seroconversion rate is the percentage of participants in a trial displaying virus-specific immune memory after being given a vaccine, while the GMT measures the level of neutralizing antibody response, Medigen said.
The experimental vaccine has a seroconversion rate of 99.8 percent and its GMT was 662 among the participants aged 20 to 89, while the gauges rose to 99.9 percent and 733 respectively in participants aged 20 to 64, the company said.
Photo: Screen grab from the Internet
No participants have shown severe adverse reactions, it said.
Only 0.7 percent of participants who were given experimental vaccines had a fever, compared with 0.4 percent in those who received a placebo, while among those who received the vaccine 27.6 percent had muscle soreness and 36 percent felt tired, compared with 16.6 percent and 29.7 percent respectively for those who were given a placebo, it said.
“It would be the regulator that decides if our experimental vaccine has good efficacy, but I personally found the results — the seroconversion rates and the GMT figures — optimistic,” Medigen chief executive officer Charles Chen (陳燦堅) said.
“And it is very safe,” Chen added.
The company will apply to the Food and Drug Administration for emergency use authorization as soon as possible, he said.
However, asked which COVID-19 vaccine developed outside Taiwan that has been granted emergency use authorization Medigen’s experimental vaccine might be compared to, the company said it has not reached a conclusion.
“An estimate needs to be done scientifically. We can conduct an immune-bridging study to compare the antibody levels in people who are given different COVID-19 vaccines, and the WHO is also trying to establish common standards for COVID-19 vaccines,” Medigen head of development Lien Chia-en (連加恩) said.
For example, Medigen’s clinical trial result of a GMT of 662 could be converted into international units (IU) and foreign vaccine developers could do likewise to enable international comparison, Lien said.
“However, this would take some time and other companies have not disclosed their data in IU yet,” he said.
Amid discussions over whether locally developed COVID-19 vaccines would be better than foreign vaccines, Chen and Medigen spokesman Leo Lee (李思賢) said that they are confident in their product and they and their families would get Medigen’s vaccine.
Medigen is to conduct phase 3 trials for its vaccine to earn approval from foreign regulators and it aims to conduct the tests in Europe, Chen said, adding that the UK recently allowed a French company to conduct phase 3 human testing there.
It costs about US$10,000 per participant in phase 3 trials, so the costs would be enormous if Medigen recruited 30,000 participants, Chen said.
Nvidia Corp yesterday unveiled its new high-speed interconnect technology, NVLink Fusion, with Taiwanese application-specific IC (ASIC) designers Alchip Technologies Ltd (世芯) and MediaTek Inc (聯發科) among the first to adopt the technology to help build semi-custom artificial intelligence (AI) infrastructure for hyperscalers. Nvidia has opened its technology to outside users, as hyperscalers and cloud service providers are building their own cost-effective AI chips, or accelerators, used in AI servers by leveraging ASIC firms’ designing capabilities to reduce their dependence on Nvidia. Previously, NVLink technology was only available for Nvidia’s own AI platform. “NVLink Fusion opens Nvidia’s AI platform and rich ecosystem for
WARNING: From Jan. 1 last year to the end of last month, 89 Taiwanese have gone missing or been detained in China, the MAC said, urging people to carefully consider travel to China Lax enforcement had made virtually moot regulations banning civil servants from making unauthorized visits to China, the Control Yuan said yesterday. Several agencies allowed personnel to travel to China after they submitted explanations for the trip written using artificial intelligence or provided no reason at all, the Control Yuan said in a statement, following an investigation headed by Control Yuan member Lin Wen-cheng (林文程). The probe identified 318 civil servants who traveled to China without permission in the past 10 years, but the true number could be close to 1,000, the Control Yuan said. The public employees investigated were not engaged in national
ALL TOGETHER: Only by including Taiwan can the WHA fully exemplify its commitment to ‘One World for Health,’ the representative offices of eight nations in Taiwan said The representative offices in Taiwan of eight nations yesterday issued a joint statement reiterating their support for Taiwan’s meaningful engagement with the WHO and for Taipei’s participation as an observer at the World Health Assembly (WHA). The joint statement came as Taiwan has not received an invitation to this year’s WHA, which started yesterday and runs until Tuesday next week. This year’s meeting of the decisionmaking body of the WHO in Geneva, Switzerland, would be the ninth consecutive year Taiwan has been excluded. The eight offices, which reaffirmed their support for Taiwan, are the British Office Taipei, the Australian Office Taipei, the
CAUSE AND EFFECT: China’s policies prompted the US to increase its presence in the Indo-Pacific, and Beijing should consider if this outcome is in its best interests, Lai said China has been escalating its military and political pressure on Taiwan for many years, but should reflect on this strategy and think about what is really in its best interest, President William Lai (賴清德) said. Lai made the remark in a YouTube interview with Mindi World News that was broadcast on Saturday, ahead of the first anniversary of his presidential inauguration tomorrow. The US has clearly stated that China is its biggest challenge and threat, with US President Donald Trump and US Secretary of Defense Pete Hegseth repeatedly saying that the US should increase its forces in the Indo-Pacific region